VBI Vaccines Receives US FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
VBI Vaccines Inc. announced that the US FDA granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma.
[Haematologica] Myeloid-derived suppressor cells (MDSCs) populations were evaluated in acquired aplastic anemia in which aberrant immune mechanisms contributed to bone marrow destruction.
[Cell Death & Disease] To investigate the effect of ellagic acid (EA) on benign prostate hyperplasia, scientists used EA, a phytochemical abundant in fruits and vegetables, to treat testosterone propionate-induced BPH rats and RWPE-1 human prostate epithelial cells.